Hero - CBD vs Ashwagandha
Home/Compare/CBD vs Ashwagandha

CBD vs Ashwagandha: One Has a Liver Safety Signal Worth Knowing

On stress and anxiety, ashwagandha has better trial data than CBD, with meta-analyses showing large effect sizes. It also has a liver injury signal serious enough that the NIH rates it a highly likely cause of clinically apparent liver injury, several European regulators have issued warnings, and Denmark banned it from food supplements in 2023. Both of those things are true, and any honest comparison has to carry them together.

Third Party TestedBatch Certificates Of AnalysisHighest QualityFull SpectrumGlobal Shipping100% Organic
Third Party TestedBatch Certificates Of AnalysisHighest QualityFull SpectrumGlobal Shipping100% Organic

At a glance

Property
Ashwagandha
CBD
What it is
Root extract of a nightshade-family shrub
A cannabis plant compound
Active constituents
Withanolides
Cannabidiol
Proposed mechanism
HPA axis and cortisol modulation, GABAergic activity. Not firmly established
ENT1 transporter, TRPA1, 5-HT1A, GPR55
Stress and anxiety evidence
Meta-analysis of 12 RCTs, n=1,002, large effect sizes, but low certainty
Meta-analysis of 8 trials, n=316, modest effect at 300 to 800 mg
Liver safety
NIH LiverTox likelihood score B, highly likely cause of clinically apparent liver injury
Transaminase elevations in around 9 percent of epilepsy trial patients
Denmark
Banned in food supplements since 2023
Not banned, but an unauthorised novel food requiring authorisation, as EU-wide
US status
Dietary supplement, no ban or warning
FDA holds it is not lawful as a supplement ingredient

The evidence on stress, honestly weighted

Ashwagandha
Ashwagandha has more supportive trial data for stress than CBD does.
A 2022 meta-analysis of 12 randomized controlled trials in 1,002 participants found a standardised mean difference of minus 1.55 for anxiety and minus 1.75 for stress, both statistically significant, with a favorable dose response between 300 and 600 mg a day.
Heterogeneity was very high, above 93 percent for anxiety, which means the trials disagreed with each other substantially. And the authors themselves rated the certainty of the evidence as low for both outcomes.
CBD
CBD's anxiety evidence is a meta-analysis of eight trials in 316 participants showing a significant effect, with a confidence interval that nearly crosses zero and doses typically of 300 to 800 mg given acutely.
Consumer CBD products deliver a fraction of that.

Neither of these is a treatment for an anxiety disorder, and neither of us can market it as one.

What people get wrong

01Ashwagandha is safe because it is natural and ancient.
Traditional use is not a safety dataset. The liver cases involved products verified to contain ashwagandha and nothing else.
02Ashwagandha lowers cortisol so it reduces stress.
The mechanism is proposed rather than established, and the trial heterogeneity is high.
03CBD and ashwagandha work better together.
No trial has tested that combination. Both are metabolized in the liver, and both have liver signals, which is a reason for caution rather than enthusiasm.
04If it were dangerous it would be banned.
In Denmark it is.

Choosing between them

If your interest is stress specifically, ashwagandha has the stronger trial signal, at 300 to 600 mg a day, and a liver safety profile you should read before deciding. Anyone with existing liver disease, thyroid disease, or who is pregnant, breastfeeding or under 18 should follow the European regulators’ advice and avoid it.

CBD has weaker anxiety evidence at doses far above what most products contain, and a better-characterized though not spotless safety profile.

Neither decision should be made from a product page. If you take any medication or have any liver condition, this is a conversation with your prescriber.

Still weighing up the options? See Lion’s mane vs ashwagandha, Reishi vs ashwagandha or CBD vs melatonin. Endoca products related to this comparison: CBD calm range.

How Endoca tests for this

We do not put ashwagandha in our products. Given the liver injury case series, the NIH likelihood score and the European bans, we are not comfortable adding it to a supplement, and in some of the markets we sell into we would not be permitted to in any case. We would rather explain that than quietly omit it.

Frequently asked questions

It has a documented liver injury signal, rated by the NIH as a likely cause of clinically apparent liver injury, with reported deaths in people with pre-existing liver disease. Several European regulators advise against it for specific groups.

Ashwagandha has the stronger trial data. That has to be weighed against its safety profile.

No trial has tested it. Both are metabolized hepatically and both have liver signals.

On the basis of a national risk assessment citing liver damage cases, hormonal effects and the conclusion that no safe intake could be determined.

No claim is authorised. Ten sit on the transitional on-hold list, which is not the same as approval.

No, ashwagandha is not a controlled substance. Some countries have restricted it on safety grounds, and Denmark banned it in 2023, so its legal status depends on where you live.

Ashwagandha trials have usually run for around eight weeks of daily use. Some CBD studies tested a single dose before a stressful task. The two have not been compared head to head.

References

01

NIH LiverTox. Ashwagandha. NIDDK, updated 3 December 2024.

02

Bjornsson HK et al. Ashwagandha-induced liver injury: A case series from Iceland and the US DILIN. Liver Int 2020;40:825-829.

03

Philips CA et al. Ashwagandha-induced liver injury: A case series from India. Hepatol Commun 2023;7:e0270.

04

Akhgarjand C et al. Effect of ashwagandha on stress and anxiety. Meta-analysis of 12 RCTs, 2022.

05

Han B et al. Cannabidiol for anxiety: meta-analysis. Psychiatry Res 2024;339:116049.

06

Williamson EM, Brendler T. Ashwagandha: Is It Safe? Part 2. Phytother Res 2026;40:4792-4801.

07

Brendler T et al. Ashwagandha: Is It Safe? Part 1: A Regulatory Review. Phytother Res 2026;40:4845-4857.

Last reviewed 1 September 2026.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.